# Section 3 ACL Elite and ACL Elite Pro 510(k) Summary

K060162

# Submitted by:

Instrumentation Laboratory Company   
113 Hartwell Avenue   
Lexington, MA 02421

# Contact Person:

Carol Marble, Regulatory Affairs Director   
Phone: 781-861-4467   
Fax: 781-861-4207

# Summary Prepared:

January 20, 2006

# Device Name:

ACL Elite and ACL Elite Pro

# Classification Name:

Regulation Section: Multipurpose system for in vitro coagulation studies (864.5425)   
Classification: Class Ⅱ   
Product Code: JPA   
Panel: Hematology

# Legally Marketed Device:

K000053

ACL 9000 (ACL 8000 and ACL 10000)

# Device Description:

The ACL Elite and ACL Elite Pro are fully automated, high-productivity analyzers designed specifically for in vitro diagnostic clinical use in the hemostasis laboratory for coagulation and/or fibrinolysis testing in the assessment of thrombosis and/or hemostasis. The systems provide results for both direct hemostasis measurements and calculated parameters.

The analytical modifications to the ACL 8000/9000/10000 introduced with the new family members (ACL Elite and ACL Elite Pro) include the following:

Modification to the test parameter (revised use of the Secondary Algorithm) for several PT and APTT assays. Addition of dedicated calibration for HemosIL Factor VII and HemosIL Factor IX Deficient Plasmas, when used in conjunction with HemosIL APTT-SP.   
• Introduction of automated factor parallelism, which is a manual function on the ACL 8000/9000/10000.

# Section 3 (Cont.) ACL Elite and ACL Elite Pro 510(k) Summary

# Statement of Technological Characteristics of the Device Compared to Predicate Device:

The indications for use/intended use, operating principle and performance claims of the ACL Elite and ACL Elite Pro are substantially equivalent to the legally marketed device, the ACL 8000/9000/10000 (K000053).

# Summary of Performance Data:

# Precision

Within run and total precision assessed over multiple runs on the ACL Elite/ACL Elite Pro using three levels of control plasma for factors deficient plasmas, APTT and PT, and two levels of control plasmas for fibrinogen gave the following results:

<table><tr><td rowspan=1 colspan=1>Test</td><td rowspan=1 colspan=5>FVIII (% Activity)</td></tr><tr><td rowspan=4 colspan=1>HemosILFactor VIII(K034007)W/ APTT-SP</td><td rowspan=1 colspan=1>Material</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within Run% CV</td><td rowspan=1 colspan=1>Total%CV</td></tr><tr><td rowspan=1 colspan=1>Normal Control</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>85.3</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>4.5</td></tr><tr><td rowspan=1 colspan=1>Special Test Control Level 1</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>72.4</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>3.6</td></tr><tr><td rowspan=1 colspan=1>Special Test Control Level 2</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>36.3</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>5.4</td></tr><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=4>FIX (% Activity)</td></tr><tr><td rowspan=4 colspan=1>HemosILFactor IX(K031829)W/ APTT-SP</td><td rowspan=1 colspan=1>Material</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within Run% CV</td><td rowspan=1 colspan=1>Total%CV</td></tr><tr><td rowspan=1 colspan=1>Normal Control</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>115.6</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>5.2</td></tr><tr><td rowspan=1 colspan=1>Special Test Control Level 1</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>76.2</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>4.5</td></tr><tr><td rowspan=1 colspan=1>Special Test Control Level 2</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>41.0</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>5.1</td></tr><tr><td rowspan=1 colspan=6>APTT (Seconds)</td></tr><tr><td rowspan=4 colspan=1>HemosILAPTT-SP(K973306)</td><td rowspan=1 colspan=1>Material</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within Run% CV</td><td rowspan=1 colspan=1>Total%CV</td></tr><tr><td rowspan=1 colspan=1>Normal Control</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>29.3</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>Low Abnormal Control</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>46.1</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>4.1</td></tr><tr><td rowspan=1 colspan=1>High Abnormal Control</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>56.9</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>4.7</td></tr><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>APT</td><td rowspan=1 colspan=1>APTT (Seconds)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=4 colspan=1>HemosILSynthASil(K953981)</td><td rowspan=1 colspan=1>Material</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within Run% CV</td><td rowspan=1 colspan=1>Total%CV</td></tr><tr><td rowspan=1 colspan=1>Normal Control</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>29.0</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>Low Abnormal Control</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>51.9</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.5</td></tr><tr><td rowspan=1 colspan=1>High Abnormal Control</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>60.5</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.2</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=1></td></tr></table>

# Section 3 (Cont.) ACL Elite and ACL Elite Pro 510(k) Summary

# Summary of Performance Data (Cont.):

Precision (Cont.)

<table><tr><td rowspan=1 colspan=1>Test</td><td rowspan=1 colspan=5>Prothrombin Time (Seconds)</td></tr><tr><td rowspan=8 colspan=1>HemosILPT-Fibrinogen(K862301)</td><td rowspan=1 colspan=1>Material</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within Run% CV</td><td rowspan=1 colspan=1>Total%CV</td></tr><tr><td rowspan=1 colspan=1>Normal Control</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>12.3</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.1</td></tr><tr><td rowspan=1 colspan=1>Low Abnormal Control</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>20.7</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.1</td></tr><tr><td rowspan=1 colspan=1>High Abnormal Control</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>25.5</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.4</td></tr><tr><td rowspan=1 colspan=5>Fibrinogen (mg/dL)</td></tr><tr><td rowspan=1 colspan=1>Material</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within Run% CV</td><td rowspan=1 colspan=1>Total%CV</td></tr><tr><td rowspan=1 colspan=1>Normal Control</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>277.9</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>4.6</td></tr><tr><td rowspan=1 colspan=1>Low Fibrinogen Control</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>132.9</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>5.5</td></tr><tr><td rowspan=9 colspan=1>HemosILPT-FibrinogenRecombinant(K981479)</td><td rowspan=1 colspan=5>Prothrombin Time (Seconds)</td></tr><tr><td rowspan=1 colspan=1>Material</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within Run% CV</td><td rowspan=1 colspan=1>Total%CV</td></tr><tr><td rowspan=1 colspan=1>Normal Control</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>10.7</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.1</td></tr><tr><td rowspan=1 colspan=1>Low Abnormal Control</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>35.0</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>High Abnormal Control</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>51.6</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>3.4</td></tr><tr><td rowspan=1 colspan=5>Fibrinogen (mg/dL)</td></tr><tr><td rowspan=1 colspan=1>Material</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within Run% CV</td><td rowspan=1 colspan=1>Total%CV</td></tr><tr><td rowspan=1 colspan=1>Normal Control</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>297.6</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>6.7</td></tr><tr><td rowspan=1 colspan=1>Low Fibrinogen Control</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>113.1</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>6.4</td></tr></table>

# Method Comparison

In comparison studies evaluating citrated plasma samples, the ACL Elite/ACL Elite Pro versus the ACL 9000 (predicate device) was shown to be statistically similar for the tests listed below:

<table><tr><td rowspan=1 colspan=1>Test</td><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>r</td></tr><tr><td rowspan=1 colspan=1>HemosIL Factor VIII</td><td rowspan=1 colspan=1>FVⅢI w/ APTT-SP (% Act.)</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>0.909</td><td rowspan=1 colspan=1>0.9938</td></tr><tr><td rowspan=1 colspan=1>HemosIL Factor IX</td><td rowspan=1 colspan=1>FIX with APTT-SP (% Act.)</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>0.948</td><td rowspan=1 colspan=1>0.9914</td></tr><tr><td rowspan=1 colspan=1>HemosIL APTT-SP</td><td rowspan=1 colspan=1>APTT (Seconds)</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>1.032</td><td rowspan=1 colspan=1>0.9990</td></tr><tr><td rowspan=1 colspan=1>HemosIL SynthASil</td><td rowspan=1 colspan=1>APTT (Seconds)</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>1.009</td><td rowspan=1 colspan=1>0.9981</td></tr><tr><td rowspan=2 colspan=1>HemosⅡLPT-Fibrinogen</td><td rowspan=1 colspan=1>PT (sec)</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>0.989</td><td rowspan=1 colspan=1>0.9985</td></tr><tr><td rowspan=1 colspan=1>Fibrinogen (mg/dL)</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>0.996</td><td rowspan=1 colspan=1>0.9848</td></tr><tr><td rowspan=2 colspan=1>HemosILPT-Fibrinogen Recombinant</td><td rowspan=1 colspan=1>PT (sec)</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>0.972</td><td rowspan=1 colspan=1>0.9993</td></tr><tr><td rowspan=1 colspan=1>Fibrinogen (mg/dL)</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>0.974</td><td rowspan=1 colspan=1>0.9992</td></tr></table>

# FEB 2 1 2006

Ms. Carol Marble   
Regulatory Affairs Director   
Instrumentation Laboratory Company   
113 Hartwell Avenue   
Lexington, MA 02421

Re: k060162 Trade/Device Name: ACL Elite and ACL Elite Pro Regulation Number: 21 CFR 864.5425 Regulation Name: Multipurpose system for in vitro coagulation studies Regulatory Class: II Product Code: JPA Dated: January 20, 2006 Received: January 23, 2006

Dear Ms. Marble:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class I (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA mav publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html

Sincerely yours,

fobeth Beckter

Robert L. Becker, Jr., MD, PK.D   
Director   
Division of Immunology and Hematology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and   
Radiological Health

# Indications for Use Statement

510(k) Number (if known): KoC00/62

Device Name: ACL Elite and ACL Elite Pro

# Indications for Use:

The ACL Elite and ACL Elite Pro are fully automated, high-productivity analyzers designed specifically for in vitro diagnostic clinical use in the hemostasis laboratory for coagulation and/or fibrinolysis testing in the assessment of thrombosis and/or hemostasis. The systems provide results for both direct hemostasis measurements and calculated parameters.

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Divisionfin   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
510(k) K060162